2025 brought no shortage of new ideas in Washington to reshape how the United States pays for medicines. From Most Favored Nation  (MFN) proposals to executive actions and broader drug pricing reforms, the policy debate moved quickly, with major implications for patients, investors, and the future of biomedical innovation.  Throughout the year, Incubate stayed at the cutting edge of that dialogue, bringing a consistent focus to what matters most: protecting access today while

September 13th -- or 9/13 Day -- is a reminder of the harmful provision in the Inflation Reduction Act commonly known as the pill...

Incubate executive director John Stanford was recently featured in an Inside Health Policy  article by reporter Gabrielle Wanneh on the pressures facing the pharmaceutical industry under President Trump's Most Favored Nation (MFN) drug pricing proposal, among other policy headwinds.  While companies are publicly emphasizing growth, Stanford cautioned that beneath the surface the investment ecosystem is being reshaped by policies like the Inflation Reduction Act's pill penalty

On June 24, Incubate executive director John Stanford joined Punchbowl News for a discussion  on the future of medicine. The culmination...

In his latest opinion piece for BioSpace , Incubate executive director John Stanford details how recent federal policy shifts are...

This week, Incubate brought its voice to Capitol Hill, convening a fly-in with Patrick Jordan of NovaQuest Capital Management and Guarav Gupta of J.P. Morgan Chase & Co. to meet with key policymakers to discuss how federal policy can better support  early-stage biopharmaceutical innovation and the venture capital ecosystem that drives it. Incubate held strategic meetings with Senators John Cornyn (R-TX), Todd Young (R-IN), and Jon Husted (R-OH), as well as the Center for Medi

Incubate executive director John Stanford was recently featured in a PharmaVoice  article by lead editor Meagan Parrish on Incubate's survey  of early-stage biotech CEOs. Respondents to Incubate's survey described  challenges to the biotech sector and cited a decline in investor interest due to regulatory pressures and other changes in Washington. The respondents' concerns included the Inflation Reduction Act's "pill penalty," tariffs on medicines, NIH funding cuts, and weake

In their new opinion piece for the Triangle Business Journal , Incubate executive director John Stanford and Patrick Jordan, managing...

President Trump recently issued an executive order  urging officials in his administration to work with Congress and end the pill penalty...

On the latest episode  of the Making Medicine podcast, Incubate executive director John Stanford sat down with Thomas Kaiser of Avicenna...

WASHINGTON ( April 16) -- Yesterday, President Trump issued an executive order  calling on Secretary of Health and Human Services Robert...

In a new executive order , President Trump called on HHS Secretary Robert F. Kennedy Jr. to work with Congress to end the "pill penalty" -- a provision in Medicare's drug pricing program that discourages investment in small molecule drugs. Ever since the Inflation Reduction Act was introduced, Incubate has worked to educate the public and policymakers alike about the detrimental impacts of the pill penalty  on life sciences research and development. An Incubate survey found 8

On March 26, Incubate executive director John Stanford joined a roundtable discussion hosted by The Hill  and the Alliance for Aging...

WASHINGTON (March 31) -- Today, Incubate launched a seven-figure advertising campaign nationwide calling on Congress to pass the...

Incubate executive director John Stanford was recently featured in a PharmaVoice  article by reporter Amy Baxter on proposed reforms to...

BioWorld  regulatory editor Mari Serebrov recently interviewed Incubate's executive director John Stanford for her article on how the...

Incubate executive director John Stanford was recently featured in an Endpoints News  article by senior editor Zachary Brennan on...

WASHINGTON, D.C. (March 5, 2025) -- This week, Senators Thom Tillis (R-NC), Ted Budd (R-NC), Marsha Blackburn (R-TN), James Lankford...

We recently tallied six new entries for our Life Sciences Investment Tracker , identifying four more research programs and two more drugs...

STAT reporter Ed Silverman recently interviewed Incubate's execute director John Stanford for an article  on the EPIC Act's...